{"id":"W4388794355","doi":"10.1038/s41416-023-02487-5","title":"Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Bristol-Myers Squibb Canada; Gateway for Cancer Research; National Cancer Institute; Celgene; Prostate Cancer Foundation","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Rash; Adverse effect; PI3K/AKT/mTOR pathway; Oncology; Cancer; Urology; Pharmacology; Gastroenterology; Clinical trial; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009422289,0.002198064,0.002277947,0.000563711,0.0004187689,0.001049622,0.001009178,0.001553944,0.006447693],"category_scores_gemma":[0.0007201501,0.0008955615,0.001490375,0.0004597093,0.001001217,0.0008073236,0.0003282683,0.003396811,0.00143375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072235,"about_ca_system_score_gemma":0.001637394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003842869,"about_ca_topic_score_gemma":0.01036296,"domain_scores_codex":[0.9997122,0.0001196549,0.00001059036,0.00005631521,0.00002206137,0.00007923516],"domain_scores_gemma":[0.9995193,0.00006337535,0.00006111436,0.00002949652,0.00002592356,0.0003006772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8496937,0.04570453,0.00170716,0.0008375264,0.001148292,0.0001491791,0.0002265806,0.002822374,0.02643266,0.0003334447,0.004396003,0.06654853],"study_design_scores_gemma":[0.6931053,0.29266,0.007428863,0.00004497326,0.0003982765,0.0001981367,0.00006250633,0.0009967226,0.002124114,0.0002299987,0.002709206,0.00004190422],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854639,0.004133883,0.0006758582,0.000830822,0.0002772672,0.002350475,0.002242129,0.0002401095,0.00378559],"genre_scores_gemma":[0.9799298,0.003508682,0.002052656,0.001131076,0.0001855709,0.002112376,0.003965469,0.00006995078,0.007044329],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006447693,"threshold_uncertainty_score":0.02156973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03455865352368256,"score_gpt":0.3647765362977197,"score_spread":0.3302178827740371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}